Aptahem (publ) announces today that Maria Ekblad has been appointed new Chief Operating Officer (COO) in the company as of 14 January 2022. Maria has long and solid experience from the [...]
Aptahem (publ) announces today that the company has signed an agreement to initiate activities (Start Up Agreement, SUA) with the clinical contract research organization (CRO) The Centre for [...]
When sepsis company Aptahem recently received its European patent and thus strengthened the protection for the drug candidate Apta-1 in eleven European countries, it was the culmination of a [...]
Aptahem AB (publ) announces today that in all countries in Europe where the company has applied for patent protection now have validated and approved the patent family 2. The patent has been [...]
BioStock published an article on 2 December 2021 about Aptahem, which can be read in full below. Aptahem’s collaboration with Örebro University recently led to a research breakthrough regarding a [...]
Aptahem can today announce that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 has started at the collaboration partner LGC Biotechnologies’ [...]
Aptahem can today announce that in a Corona virus challenge induced Acute Lung Injury model studies with Apta-1 treatment shows strong evidence in maintaining systemic circulation, protection of [...]
It is time for 2021’s edition of the largest partnering meeting in the life science space – BIO-Europe. This week, representatives from nearly 1,500 companies will gather to establish new [...]
On Thursday 21 October 2021 at 11.40 CET, CEO Mikael Lindstam will present the latest development in Aptahem and the lead candidate Apta-1 at the BioStock Life Science Summit. The event can be [...]
Aptahem AB (publ) announces today that the Turkish patent office has approved the patent application as the first validated country in Europe. The patent was published with the patent number [...]
